Forget Mylan N.V.'s Dismal Third-Quarter Results -- Its Future Is Looking Better
When Mylan N.V. (NASDAQ: MYL) reported its second-quarter results in August, there wasn't much good news except for the positive impact from its acquisitions. The drugmaker slashed its full-year earnings guidance because of expected delays in U.S. generic drug launches.
But there was considerably more optimism in the air when Mylan's announced its third-quarter results before the market opened on Monday. Those results weren't all that great, but the company expressed confidence that its fortunes would improve in the fourth quarter and into 2018. Here are the highlights.
Image source: Getty Images.
Source: Fool.com
